Subsequent studies demonstrated that plerixafor elevates CD34+ cell harvests in comparison to G-CSF alone in healthy volunteers36 and NHL and MM patients.37-39 Therefore, plerixafor was approved in combination with G-CSF for HSPC mobilization for autologous transplantation in lymphoma and MM patients. This evidence concerns the gene CD34 and Miyoshi myopathy.